Your browser doesn't support javascript.
loading
Unanswered questions in prostate cancer - findings of an international multi-stakeholder consensus by the PIONEER consortium.
Omar, Muhammad Imran; MacLennan, Steven; Ribal, Maria J; Roobol, Monique J; Dimitropoulos, Konstantinos; van den Broeck, Thomas; MacLennan, Sara J; Axelsson, Susan Evans; Gandaglia, Giorgio; Willemse, Peter-Paul; Mastris, Ken; Ransohoff, John Butler; Devecseri, Zsuzsanna; Abbott, Thomas; De Meulder, Bertrand; Bjartell, Anders; Asiimwe, Alex; N'Dow, James.
Afiliação
  • Omar MI; Academic Urology Unit, University of Aberdeen, Aberdeen, UK. m.i.omar@abdn.ac.uk.
  • MacLennan S; Guidelines Office, European Association of Urology, Arnhem, Netherlands. m.i.omar@abdn.ac.uk.
  • Ribal MJ; Academic Urology Unit, University of Aberdeen, Aberdeen, UK.
  • Roobol MJ; Guidelines Office, European Association of Urology, Arnhem, Netherlands.
  • Dimitropoulos K; Erasmus MC, Rotterdam, Netherlands.
  • van den Broeck T; Academic Urology Unit, University of Aberdeen, Aberdeen, UK.
  • MacLennan SJ; Guidelines Office, European Association of Urology, Arnhem, Netherlands.
  • Axelsson SE; Academic Urology Unit, University of Aberdeen, Aberdeen, UK.
  • Gandaglia G; Bayer AG, Berlin, Germany.
  • Willemse PP; Department of Urology and Division of Experimental Oncology, Urological Research Institute, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Mastris K; Guidelines Office, European Association of Urology, Arnhem, Netherlands.
  • Ransohoff JB; European Cancer Patient Coalition, Brussels, Belgium.
  • Devecseri Z; Bayer AG, Berlin, Germany.
  • Abbott T; Sanofi, Chilly-Mazarin, France.
  • De Meulder B; Astellas, Leiden, Netherlands.
  • Bjartell A; Association EISBM, Vourles, France.
  • Asiimwe A; Department of Translational Medicine, Lund University, Lund, Sweden.
  • N'Dow J; Bayer AG, Berlin, Germany.
Nat Rev Urol ; 20(8): 494-501, 2023 08.
Article em En | MEDLINE | ID: mdl-37012441
ABSTRACT
PIONEER is a European network of excellence for big data in prostate cancer consisting of 37 private and public stakeholders from 9 countries across Europe. Many progresses have been done in prostate cancer management, but unanswered questions in the field still exist, and big data could help to answer these questions. The PIONEER consortium conducted a two-round modified Delphi survey aiming at building consensus between two stakeholder groups - health-care professionals and patients with prostate cancer - about the most important questions in the field of prostate cancer to be answered using big data. Respondents were asked to consider what would be the effect of answering the proposed questions on improving diagnosis and treatment outcomes for patients with prostate cancer and to score these questions on a scale of 1 (not important) to 9 (critically important). The mean percentage of participants who scored each of the proposed questions as critically important was calculated across the two stakeholder groups and used to rank the questions and identify the highest scoring questions in the critically important category. The identification of questions in prostate cancer that are important to various stakeholders will help the PIONEER consortium to provide answers to these questions to improve the clinical care of patients with prostate cancer.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies Limite: Humans / Male País/Região como assunto: Europa Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies Limite: Humans / Male País/Região como assunto: Europa Idioma: En Ano de publicação: 2023 Tipo de documento: Article